Martin Boegemann

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Matthew R. Smith, Chris Parker, Fred Saad et al. · The Lancet Oncology · 2019 · 397 citations · Full text

Medicine, Oncology, Urology +16

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Kim N., Dana E. Rathkopf, Matthew R. Smith et al. · Journal of Clinical Oncology · 2023 · 319 citations · Full text

Medicine, Oncology, Urology +17

Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone

Andres Jan Schrader, Martin Boegemann, Carsten-H. Ohlmann et al. · European Urology · 2013 · 285 citations

Medicine, Oncology, Pharmacology +10

PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival

Kambiz Rahbar, Martin Boegemann, Anna Yordanova et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2017 · 160 citations

Medicine, Oncology, Pharmacology +17